- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01240486
IMPAACT P1073: Study of IRIS for Infants and Children Initiating HAART at Int'l Sites
IMPAACT P1073: Study Of Immune Reconstitution Inflammatory Syndrome (IRIS) For International Sites Initiating Highly Active Antiretroviral Therapy (HAART) In Infants And Children < 72 Months Of Age
Study Overview
Detailed Description
IMPAACT P1073 is a prospective clinical, observational and pathogenesis study of HIV-infected infants and children who are ART-naïve and will be initiating a HAART regimen at an IMPAACT study site. Where possible, infants and children co-enrolled in IMPAACT studies will be given preference for enrollment in P1073.
The plan is to enroll subjects in P1073 at a timepoint ≤ 1 week prior to starting HAART. For DMC purposes, this is Step 1 for P1073, and subjects are designated as a Non-case, according to the Study Flow Chart
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Maharashtra
-
Pune, Maharashtra, India, 411001
- BJ Medical College CRS (31441)
-
-
-
-
-
Cape Town, South Africa
- University of Stellenbosch, Tygerberg Hospital (8950)
-
Johannesburg, South Africa, 2013
- Soweto IMPAACT CRS (8052)
-
-
KwaZulu-Natal
-
Durban, KwaZulu-Natal, South Africa, 50202
- Durban Pediatric HIV CRS (20201)
-
-
-
-
Moshi
-
IDC Research Offices, Moshi, Tanzania
- Kilimanjaro Christian Medical CRS (12901)
-
-
-
-
-
Kampala, Uganda
- Makerere University - JHU Research Collaboration (30293)
-
-
-
-
-
Harare, Zimbabwe
- UZ-Parirenyatwa CRS (30313)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria
Past or current documentation of a confirmed diagnosis of HIV-1 infection. Documentation of HIV-1 infection is defined as positive results from two samples collected at different time points. All samples tested must be whole blood, serum, or plasma.
- Sample #1 may be tested by non-study public or PEPFAR programs. However, both the result and the assay date must be recorded in subject's chart. Source documentation (patient's medical record/chart, Ministry of Health (MOH) registers, laboratory results, etc.) must be available if requested.
- Sample #2 must be performed in a CAP/CLIA-approved laboratory (for US sites) or in a laboratory that operates according to GCLP guidelines and participates in an appropriate external quality assurance program (for international sites).
For P1073, the subject may be enrolled before the result of Sample #2 is available. However, the subject will be taken off study should the 2nd result be negative.
Acceptable tests when subjects are ≤ 18 months of age
Sample #1 may be tested using any of the following: One HIV DNA PCR; One quantitative HIV RNA PCR (>5,000 copies/mL); One qualitative HIV RNA PCR; One total HIV nucleic acid test
**If Sample #1 is positive, collect and test Sample #2.
- Sample #2 may be tested using any of the assays listed above for Sample #1.
Acceptable tests when subjects are > 18 months of age
Sample #1 may be tested using any of the following: Two rapid antibody tests from different manufacturers or based on different principles and epitopes; One EIA OR Western Blot OR immunofluorescence OR chemiluminescence; One HIV DNA PCR; One quantitative HIV RNA PCR (>5,000 copies/mL; One qualitative HIV RNA PCR; One HIV culture (prior to August 2009); One total HIV nucleic acid test
**If Sample #1 is positive, then collect and test Sample #2.
Sample #2 may be tested using any of the following: One EIA confirmed by Western Blot OR immunofluorescence OR chemiluminescence; One HIV DNA PCR; One quantitative HIV RNA PCR (>5,000 copies/mL); One qualitative HIV RNA PCR; One HIV culture (prior to August 2009;)One total HIV nucleic acid test
- Rapid antibody tests are not allowed for sample #2
Age: range is ≥ 4 weeks to < 72 months of age at time of HAART initiation.
*All infants and children ≥ 4 weeks to < 72 months of age, who are about to initiate HAART according to National or WHO criteria, are eligible.
- HIV-infected infants and children who meet the ART guidelines of local programs or an IMPAACT or other protocol and who can be enrolled ≤ 1 week prior to starting HAART.
- No known active untreated opportunistic infection.
- Infants ≤ 12 months of age should have received BCG immunization and the date of BCG vaccine has to be known.
- Legal guardian able and willing to provide signed informed consent for participating in the IRIS study.
Exclusion Criteria
-Any clinically significant diseases (other than HIV infection) e.g. malignancy, auto-immune or inflammatory diseases requiring long-term immunosuppressive therapy, or clinically significant findings during the screening medical history or physical examination that, in the investigator's opinion, would compromise the outcome of this study. Please contact the team at actg.teamp1073@fstrf.org.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of study subjects having BCG-related IRIS within 48 weeks of initiating HAART.
Time Frame: within 48 weeks of iniating HAART
|
within 48 weeks of iniating HAART
|
Proportion of study subjects having unmasking and paradoxical TB-related IRIS within 48 weeks of initiating HAART.
Time Frame: Within 48 weeks of initiating HAART
|
Within 48 weeks of initiating HAART
|
Nadir CD4 T-cell count and percentage and plasma viral load pre-HAART initiation, and two weeks post-HAART and CD4 T-cell count and percentage and plasma viral load at the presumptive BCG or TB-IRIS event, for CASES and the matching controls.
Time Frame: At Study Entry, 2 weeks post-HAART and within 48 weeks of initiating HAART
|
At Study Entry, 2 weeks post-HAART and within 48 weeks of initiating HAART
|
CD4 T-cell count and percentage and plasma viral load, 48 weeks post-HAART initiation for CASES and the matching controls.
Time Frame: 48 weeks post-HAART
|
48 weeks post-HAART
|
Frequency of all IRIS-like events and proportion attributed to BCG or TB.
Time Frame: within 48 weeks of initiating HAART
|
within 48 weeks of initiating HAART
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Mark Cotton, MD, IMPAACT/Stellenbosch University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- IMPAACT P1073
- U01AI068632 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States